menu
    • menu
    [{"orgOrder":0,"company":"R-Pharm","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"||Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"R-Pharm \/ AstraZeneca","highestDevelopmentStatusID":"7","companyTruncated":"R-Pharm \/ AstraZeneca"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Gam-COVID-Vac Lyo","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"The Gamaleya National Center of Epidemiology and Microbiology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"The Gamaleya National Center of Epidemiology and Microbiology \/ Inapplicable"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            R-Pharm

                            Russia arrow
                            IFT FIRST
                            Not Confirmed

                            R-Pharm

                            Russia arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ChAdOx1 nCoV-19,rAd26-S

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Azerbaijan issues Permit to Conduct World’s First Clinical Trials of Vaccine Combination, Sputnik V and COVI...

                            Details : The research aimed to evaluate the immunogenicity and safety of the Sputnik V and AZD1222 combined use. The research program will take place in several countries, enrolling 100 adults aged 18 years and older.

                            Product Name : AZD1222

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 02, 2021

                            Lead Product(s) : ChAdOx1 nCoV-19,rAd26-S

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            The Gamaleya National Center of Epidemiology and Microbiology

                            Russia arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gam-COVID-Vac Lyo

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Russia May Start Phase III Tial of COVID-19 Vaccine in Mid-August: RIA

                            Details : Early results from the first small-scale human trial of the vaccine developed by the Gamaleya Institute in Moscow has shown it to be safe for use, according to a separate RIA report on Sunday.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 13, 2020

                            Lead Product(s) : Gam-COVID-Vac Lyo

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth